Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, S. | - |
dc.contributor.author | Park, C. -Y. | - |
dc.contributor.author | Han, K. A. | - |
dc.contributor.author | Chung, C. H. | - |
dc.contributor.author | Ku, B. J. | - |
dc.contributor.author | Jang, H. C. | - |
dc.contributor.author | Ahn, C. W. | - |
dc.contributor.author | Lee, M. -K. | - |
dc.contributor.author | Moon, M. K. | - |
dc.contributor.author | Son, H. S. | - |
dc.contributor.author | Lee, C. B. | - |
dc.contributor.author | Cho, Y. -W. | - |
dc.contributor.author | Park, S. -W. | - |
dc.date.accessioned | 2021-07-30T05:28:25Z | - |
dc.date.available | 2021-07-30T05:28:25Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5050 | - |
dc.description.abstract | We assessed the 24-week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study. Patients (n = 142) were randomized 2 : 1 into two different treatment groups as follows: 99 received teneligliptin (20 mg) and 43 received placebo. The primary endpoint was change in glycated haemoglobin (HbA1c) level from baseline to week 24. Teneligliptin significantly reduced the HbA1c level from baseline compared with placebo after 24weeks. At week 24, the differences between changes in HbA1c and fasting plasma glucose (FBG) in the teneligliptin and placebo groups were -0.94% [least-squares (LS) mean -1.22, -0.65] and -1.21 mmol/l (-1.72, -0.70), respectively (all p < 0.001). The incidence of hypoglycaemia and adverse events were not significantly different between the two groups. This phase III, randomized, placebo-controlled study provides evidence of the safety and efficacy of 24weeks of treatment with teneligliptin as a monotherapy in Korean patients with T2DM. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, S. | - |
dc.contributor.affiliatedAuthor | Lee, C. B. | - |
dc.identifier.doi | 10.1111/dom.12631 | - |
dc.identifier.scopusid | 2-s2.0-84960883640 | - |
dc.identifier.wosid | 000374280900011 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.18, no.5, pp.528 - 532 | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 18 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 528 | - |
dc.citation.endPage | 532 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | DRUG-NAIVE PATIENTS | - |
dc.subject.keywordPlus | BETA-CELL FUNCTION | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | VILDAGLIPTIN | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | HYPERGLYCEMIA | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | STATEMENT | - |
dc.subject.keywordAuthor | antidiabetic drug | - |
dc.subject.keywordAuthor | DPP-IV inhibitor | - |
dc.subject.keywordAuthor | phase III study | - |
dc.subject.keywordAuthor | type 2 diabetes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.